Max Planck Partners with Themis Bioscience to Develop Oncolytic Virotherapies

Themis Bioscience said it will expand its measles vector immunomodulation portfolio into immuno-oncology through an exclusive global license agreement with the technology transfer agency of the Max Planck Society to develop and commercialize oncolytic virotherapies.The licensing deal between Themis and Max-Planck-Innovation—whose value was not disclosed—covers therapies based on an oncolytic measles virus platform jointly developed by the Max Planck Institute for Biochemistry and Ebe